The acquisition will add Sound Surgical’s Vaser product lines and other technologies, which uses low frequency ultrasound, to Solta’s Liposonix and Thermage treatments therapy products used for body contouring and skin tightening.

Based on revenue generated from Sound Surgical’s products in 2013, Sound Surgical unit holders will receive up to $9.5m of contingent payments, that would be paid in Solta common stock.

The transaction is expected to be accretive to Solta Medical within 12 months.

Solta Medical chairman, president and chief executive officer Stephen Fanning said, "Sound Surgical generated strong revenue and EBITDA in 2012 and we anticipate the acquisition will contribute to our bottom-line within 12 months."